Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. Until today this year the stock’s price performance recorded a decrease of -1.51%. However, over the last six months, the performance has been weaker by 38.74%. The price of BMY decreased -1.67% over the last 30 days. And in the last five days, it has fallen by -1.72%.
Bristol-Myers Squibb Co experienced a somewhat steady performance in the stock market. The company’s stock reached a 1-year high of $61.08 on 11/11/24, while the lowest price for the same period was registered at $39.35 on 07/05/24.
52-week price history of BMY Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Bristol-Myers Squibb Co’s current trading price is -8.80% away from its 52-week high, while its distance from the 52-week low is 41.56%. The stock’s price range during this period has varied between$39.35 and $61.08. The Bristol-Myers Squibb Co’s shares, which operate in the Healthcare, saw a trading volume of around 2.3 million for the day, a figure considerably lower than their average daily volume of 10.58 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Bristol-Myers Squibb Co (BMY) has experienced a quarterly rise of 6.71% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 112.98B and boasts a workforce of 34100 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 54.10, with a change in price of +6.60. Similarly, Bristol-Myers Squibb Co recorded 10,670,605 in trading volume during the last 100 days, posting a change of +13.49%.
BMY’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for BMY stands at 3.00. Similarly, the long-term debt-to-equity ratio is also 2.93.
BMY Stock Stochastic Average
As of today, Bristol-Myers Squibb Co’s raw stochastic average for the last 50 days stands at 26.93%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 20.75%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 19.34% and 28.58%, respectively.
